High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients
A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Compare High-intensity Rosuvastatin to Moderate-intensity Rosuvastatin/Ezetimibe in Atherosclerotic Cardiovascular Disease (ASCVD) Patients
Sponsor: Yuhan Corporation
Listed as NCT03494270, this PHASE4 trial focuses on ASCVD and remains completed. Sponsored by Yuhan Corporation, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jul 2019 — Jan 2020 [monthly]
Recruiting PHASE4
-
Nov 2018 — Jul 2019 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE4
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE4
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Yuhan Corporation
For direct contact, visit the study record on ClinicalTrials.gov .